Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 2,022 | 1,788 | 1,112 | 3,411 | 3,604 |
| Gross Profit | 2,022 | 1,788 | 1,112 | 3,411 | 3,604 |
| Operating Expenses | 21,954 | 27,686 | 22,411 | 27,741 | 19,850 |
| Operating Income | -19,932 | -25,898 | -21,299 | -24,330 | -16,246 |
| Interest Expense | 22 | 24 | 27 | 29 | 713 |
| Other Income | 1,169 | 398 | 398 | 298 | 64,700 |
| Pre-tax Income | -18,785 | -25,524 | -20,928 | -24,061 | 47,741 |
| Net Income Continuous | -18,785 | -25,524 | -20,928 | -24,061 | 47,741 |
| Net Income | $-18,785 | $-25,524 | $-20,928 | $-24,061 | $47,741 |
| EPS Basic Total Ops | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 |
| EPS Basic Continuous Ops | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 |
| EPS Diluted Total Ops | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 |
| EPS Diluted Continuous Ops | -0.07 | -0.10 | -0.09 | -0.10 | 0.63 |
| EPS Diluted Before Non-Recurring Items | -0.07 | -0.09 | -0.09 | N/A | N/A |
| EBITDA(a) | $-19,628 | $-25,604 | $-20,977 | $-24,005 | $-15,880 |